Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, Martinelli G, Rambaldi A, Bosi A. Lanza F, et al. Among authors: laszlo d. Transfusion. 2014 Feb;54(2):331-9. doi: 10.1111/trf.12265. Epub 2013 Jun 19. Transfusion. 2014. PMID: 23781769
Plerixafor: what we still have to learn.
Lanza F, Gardellini A, Laszlo D, Martino M. Lanza F, et al. Among authors: laszlo d. Expert Opin Biol Ther. 2015 Feb;15(2):143-7. doi: 10.1517/14712598.2015.971750. Epub 2014 Oct 15. Expert Opin Biol Ther. 2015. PMID: 25315706
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E. Arcaini L, et al. Among authors: laszlo d. Leuk Res. 2011 Jun;35(6):712-4. doi: 10.1016/j.leukres.2010.12.036. Epub 2011 Jan 26. Leuk Res. 2011. PMID: 21276613 Clinical Trial.
Who should be really considered as a poor mobilizer in the plerixafor era?
Andreola G, Vanazzi A, Radice D, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D. Andreola G, et al. Among authors: laszlo d. Transfus Apher Sci. 2012 Aug;47(1):27-32. doi: 10.1016/j.transci.2012.03.004. Epub 2012 Apr 4. Transfus Apher Sci. 2012. PMID: 22480954
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.
Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation). Lanza F, et al. Among authors: laszlo d. Am J Hematol. 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. Am J Hematol. 2017. PMID: 28612372 Free article. No abstract available.
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
Zannetti BA, Saraceni F, Cellini C, Fabbri E, Monaco F, Guarini A, Laszlo D, Martino M, Olivieri A, Imola M, Tosi P, Chiarucci M, Zuffa E, Lanza F. Zannetti BA, et al. Among authors: laszlo d. Transplant Cell Ther. 2021 Mar;27(3):244.e1-244.e8. doi: 10.1016/j.jtct.2020.12.009. Epub 2021 Jan 28. Transplant Cell Ther. 2021. PMID: 33781522 Free article.
139 results